PMADS

Id:	acc3264
Group:	2sens
Protein:	Bim
Gene Symbol:	BCL2L11
Protein Id:	O43521
Protein Name:	B2L11_HUMAN
PTM:	phosphorylation
Site:	unclear
Site Sequence:
Disease Category:	Cancer
Disease:	Leukemia
Disease Subtype:
Disease Cellline:	Jurkat T
Disease Info:
Drug:	nocodazole
Drug Info:	"Nocodazole is a drug commonly used in cell biology experiments, which can disrupt microtubule assembly."
Effect:	modulate
Effect Info:	"NOC promotes Bak activation and mitochondrial apoptosis by inducing stasis in the early and middle stages, activating Cdk1-mediated phosphorylation of Bcl-2 and Bim, and reducing their binding to Bak."
Note:
Score:	4.0
Pubmed(PMID):	24166139
Sentence Index:	24166139_9-10
Sentence:	"NOC-induced phosphorylation of Bcl-2 and Bim, Deltapsim loss, and mitochondria-dependent apoptotic events were significantly suppressed by a Cdk1 inhibitor roscovitine, but not by the JNK inhibitor SP600125 or the p38 MAPK inhibitor SB203580. These results show that the prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim, which was mediated by Cdk1, could reduce the association of Bcl-2 with Bak or Bim to allow Bak activation and mitochondrial apoptotic events in Jurkat T cells exposed to NOC."

Sequence & Structure:

MAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQGNPEGNHGGEGDSCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRVFLNNYQAAEDHPRMVILRLLRYIVRLVWRMH

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

BCL2L11-Ser104
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

BCL2L11-Ser118
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

BCL2L11-Ser77
Cancer	Intensity
BRCA	-1.869
COAD
HGSC	1.655
ccRCC	0.169
GBM
HNSC	0.422
LUAD	0.134
LUSC	-0.138
non_ccRCC	0.29
PDAC
UCEC	-0.663

BCL2L11-Ser92
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

BCL2L11-Ser93
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

BCL2L11-Ser94
Cancer	Intensity
BRCA	-1.664
COAD
HGSC	1.002
ccRCC	-0.246
GBM
HNSC	-0.477
LUAD	0.629
LUSC	-0.105
non_ccRCC	1.47
PDAC
UCEC	-0.61

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	87	U	Chronic lymphocytic leukemia	Phosphorylation	30923040

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb